Target species
Dogs
Indications for use
Active immunisation of dogs to:
-prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae
-prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola.
-prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa.
- prevent mortality, clinical signs, renal infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni.**
Onset of immunity: 2 weeks after the second injection of the primary vaccination course for all strains
Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains
* For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity.
** For Leptospira Copenhageni the duration of immunity was not established
Contra-indications
None
Special warnings for each target species
Vaccinate healthy animals only.
Special precautions for use in animals
Apply usual aseptic procedures.
Special precautions to be taken by the person administering the product to animals:
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Adverse reactions
A slight swelling (≤ 2 cm) at the injection site may commonly be observed after injection. It usually regresses within 1-6 days. This can, on some occasions, be accompanied by slight pruritus, heat and pain at the injection site. Transient lethargy and emesis may also commonly be observed.
Anorexia, polydipsia, hyperthermia, diarrhoea, muscle tremor, muscle weakness and injection site cutaneous lesions may uncommonly be observed.
Hypersensitivity reactions (facial oedema, anaphylactic shock, urticaria) may rarely occur, some of which are life-threatening. Appropriate symptomatic treatment should promptly be provided.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).
Use during pregnancy, lactation or lay
Can be used during pregnancy
Interactions
The product can be mixed with Boehringer Ingelheim live attenuated vaccines against distemper, adenovirosis, parvovirosis and parainfluenza type 2 respiratory infections. Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Boehringer Ingelheim's rabies vaccine in dogs from 12 weeks of age. Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Boehringer Ingelheim's rabies vaccine in dogs from 12 weeks of age. In that case, the efficacy against Leptospira Icterohaemorrhagiae was demonstrated only for the reduction of renal lesions and bacterial excretion, and the efficacy against Leptospira Grippotyphosa was demonstrated only for the reduction of renal carriage, renal lesions and bacterial excretion. Efficacy of the vaccine for protection against the Copenhageni serovar has not been investigated after use with Boehringer Ingelheim’s rabies vaccine on the same day.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Amounts to be administered and administration route
When Eurican Lmulti is used alone, inject a 1-ml dose subcutaneously.
When Eurican Lmulti is used as a diluent of a Boehringer Ingelheim freeze-dried vaccine against distemper, adenovirosis, parvovirosis and parainfluenza type 2, aseptically reconstitute the contents of the lyophilisate with the suspension for injection. Shake well before use. The entire contents of the reconstituted vial should be administered as a single dose.
The following schedule should be followed:
Primary vaccination: Two injections separated by an interval of 4 weeks from 7 weeks of age.
Revaccination: Administer one dose 12 months after completion of the primary vaccination course. Dogs should be revaccinated with a single booster dose on an annual basis.
Overdose
No other adverse reactions other than those mentioned in the Adverse Reactions Section were observed after administration of a 2-fold overdose.